Does the media refer more to SANA or SRZN?

In the previous week, Surrozen had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Surrozen and 3 mentions for Sana Biotechnology. Surrozen's average media sentiment score of 1.05 beat Sana Biotechnology's score of 0.20 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Surrozen 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SRZN or ABUS?

Arbutus Biopharma has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 73.40 -$242.03M -$37.59 N/A Arbutus Biopharma $14.08M 62.01 -$33.50M $0.83 5.33

Does the media refer more to SRZN or ABUS?

In the previous week, Surrozen had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Surrozen and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Surrozen's score of 1.05 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ESPR or SRZN?

In the previous week, Surrozen had 4 more articles in the media than Esperion Therapeutics. MarketBeat recorded 6 mentions for Surrozen and 2 mentions for Esperion Therapeutics. Surrozen's average media sentiment score of 1.05 beat Esperion Therapeutics' score of 0.00 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Surrozen 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, KURA or SRZN?

Surrozen has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kura Oncology $67.48M 12.46 -$278.67M -$3.35 N/A Surrozen $3.48M 73.40 -$242.03M -$37.59 N/A

Is KURA or SRZN more profitable?

Kura Oncology has a net margin of -411.19% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Kura Oncology -411.19% -141.95% -43.28% Surrozen -4,810.50% N/A -154.08%

Does the media prefer KURA or SRZN?

In the previous week, Kura Oncology and Kura Oncology both had 6 articles in the media. Surrozen's average media sentiment score of 1.05 beat Kura Oncology's score of 0.64 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Surrozen 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SRZN or ANNX?

Annexon has lower revenue, but higher earnings than Surrozen. Annexon is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 73.40 -$242.03M -$37.59 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is SRZN or ANNX more profitable?

Annexon has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% N/A -154.08% Annexon N/A -101.19% -75.99%

Does the media favor SRZN or ANNX?

In the previous week, Surrozen and Surrozen both had 6 articles in the media. Annexon's average media sentiment score of 1.21 beat Surrozen's score of 1.05 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Surrozen (SRZN) Competitors

$22.00 +0.22 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$22.08 +0.09 (+0.39%)

As of 04:10 PM Eastern

Compare

SRZN vs. SANA, ABUS, ESPR, KURA, and ANNX

Should you buy Surrozen stock or one of its competitors? MarketBeat compares Surrozen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surrozen include Sana Biotechnology (SANA), Arbutus Biopharma (ABUS), Esperion Therapeutics (ESPR), Kura Oncology (KURA), and Annexon (ANNX).

How does Surrozen compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Sana Biotechnology has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Surrozen	-4,810.50%	N/A	-154.08%

Surrozen has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Surrozen	$3.48M	73.40	-$242.03M	-$37.59	N/A

Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Sana Biotechnology presently has a consensus price target of $9.50, indicating a potential upside of 179.41%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 90.91%. Given Sana Biotechnology's higher possible upside, research analysts plainly believe Sana Biotechnology is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Surrozen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Surrozen had 3 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Surrozen and 3 mentions for Sana Biotechnology. Surrozen's average media sentiment score of 1.05 beat Sana Biotechnology's score of 0.20 indicating that Surrozen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surrozen	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Surrozen beats Sana Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Surrozen compare to Arbutus Biopharma?

Surrozen (NASDAQ:SRZN) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Arbutus Biopharma has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	73.40	-$242.03M	-$37.59	N/A
Arbutus Biopharma	$14.08M	62.01	-$33.50M	$0.83	5.33

66.6% of Surrozen shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 83.95% compared to Surrozen's net margin of -4,810.50%. Arbutus Biopharma's return on equity of 129.32% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Arbutus Biopharma	83.95%	129.32%	112.24%

In the previous week, Surrozen had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Surrozen and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Surrozen's score of 1.05 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Surrozen has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Surrozen currently has a consensus target price of $42.00, suggesting a potential upside of 90.91%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 13.12%. Given Surrozen's stronger consensus rating and higher probable upside, equities analysts plainly believe Surrozen is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Arbutus Biopharma beats Surrozen on 9 of the 17 factors compared between the two stocks.

How does Surrozen compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Esperion Therapeutics presently has a consensus target price of $5.54, suggesting a potential upside of 74.21%. Surrozen has a consensus target price of $42.00, suggesting a potential upside of 90.91%. Given Surrozen's stronger consensus rating and higher probable upside, analysts clearly believe Surrozen is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Surrozen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Esperion Therapeutics has higher revenue and earnings than Surrozen. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Surrozen	$3.48M	73.40	-$242.03M	-$37.59	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Surrozen	-4,810.50%	N/A	-154.08%

In the previous week, Surrozen had 4 more articles in the media than Esperion Therapeutics. MarketBeat recorded 6 mentions for Surrozen and 2 mentions for Esperion Therapeutics. Surrozen's average media sentiment score of 1.05 beat Esperion Therapeutics' score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surrozen	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Surrozen beats Esperion Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Surrozen compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Surrozen has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.46	-$278.67M	-$3.35	N/A
Surrozen	$3.48M	73.40	-$242.03M	-$37.59	N/A

In the previous week, Kura Oncology and Kura Oncology both had 6 articles in the media. Surrozen's average media sentiment score of 1.05 beat Kura Oncology's score of 0.64 indicating that Surrozen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology has a net margin of -411.19% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Surrozen	-4,810.50%	N/A	-154.08%

66.6% of Surrozen shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kura Oncology has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Kura Oncology currently has a consensus price target of $25.46, indicating a potential upside of 168.87%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 90.91%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Kura Oncology is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Surrozen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Surrozen beats Kura Oncology on 9 of the 16 factors compared between the two stocks.

How does Surrozen compare to Annexon?

Surrozen (NASDAQ:SRZN) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Surrozen and Surrozen both had 6 articles in the media. Annexon's average media sentiment score of 1.21 beat Surrozen's score of 1.05 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has lower revenue, but higher earnings than Surrozen. Annexon is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	73.40	-$242.03M	-$37.59	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Surrozen has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Annexon has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Annexon	N/A	-101.19%	-75.99%

Surrozen currently has a consensus target price of $42.00, indicating a potential upside of 90.91%. Annexon has a consensus target price of $15.33, indicating a potential upside of 187.68%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Annexon beats Surrozen on 8 of the 15 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$255.42M	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.59	7.36	279.72	25.54
Price / Sales	73.40	1,274.64	648.71	115.96
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-1.15	17.08	11.12	6.36
Net Income	-$242.03M	-$12.52M	$3.48B	$347.58M
7 Day Performance	13.40%	2.52%	2.59%	3.17%
1 Month Performance	-11.72%	-5.36%	-2.79%	-2.06%
1 Year Performance	105.51%	51.37%	64.29%	21.19%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	3.0053 of 5 stars	$22.00 +1.0%	$42.00 +90.9%	+98.0%	$255.42M	$3.48M	N/A	80	Positive News High Trading Volume
SANA Sana Biotechnology	2.152 of 5 stars	$3.08 -6.5%	$9.50 +208.7%	-18.7%	$858.53M	N/A	N/A	380	Upcoming Earnings
ABUS Arbutus Biopharma	2.0056 of 5 stars	$4.30 -2.6%	$5.00 +16.4%	+33.3%	$848.43M	$14.08M	5.17	90	Positive News Upcoming Earnings Gap Up
ESPR Esperion Therapeutics	1.6143 of 5 stars	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200
KURA Kura Oncology	3.3686 of 5 stars	$9.02 -3.2%	$25.46 +182.4%	+52.7%	$800.97M	$67.48M	N/A	130	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. SANA, ABUS, ESPR, KURA, and ANNX

How does Surrozen compare to Sana Biotechnology?

Summary

How does Surrozen compare to Arbutus Biopharma?

Summary

How does Surrozen compare to Esperion Therapeutics?

Summary

How does Surrozen compare to Kura Oncology?

Summary

How does Surrozen compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. SANA, ABUS, ESPR, KURA, and ANNX

How does Surrozen compare to Sana Biotechnology?

Is SANA or SRZN more profitable?

Which has preferable earnings and valuation, SANA or SRZN?

Which has more risk & volatility, SANA or SRZN?

Do analysts recommend SANA or SRZN?

Does the media refer more to SANA or SRZN?

Do institutionals and insiders believe in SANA or SRZN?

Summary

How does Surrozen compare to Arbutus Biopharma?

Which has better earnings and valuation, SRZN or ABUS?

Do insiders & institutionals hold more shares of SRZN or ABUS?

Is SRZN or ABUS more profitable?

Does the media refer more to SRZN or ABUS?

Which has more volatility & risk, SRZN or ABUS?

Do analysts rate SRZN or ABUS?

Summary

How does Surrozen compare to Esperion Therapeutics?

Do analysts prefer ESPR or SRZN?

Which has more volatility and risk, ESPR or SRZN?

Do institutionals and insiders hold more shares of ESPR or SRZN?

Which has higher earnings & valuation, ESPR or SRZN?

Is ESPR or SRZN more profitable?

Does the media prefer ESPR or SRZN?

Summary

How does Surrozen compare to Kura Oncology?

Which has better valuation and earnings, KURA or SRZN?

Does the media prefer KURA or SRZN?

Is KURA or SRZN more profitable?

Do insiders & institutionals believe in KURA or SRZN?

Which has more risk and volatility, KURA or SRZN?

Do analysts rate KURA or SRZN?

Summary

How does Surrozen compare to Annexon?

Does the media favor SRZN or ANNX?

Which has higher earnings and valuation, SRZN or ANNX?

Which has more volatility and risk, SRZN or ANNX?

Is SRZN or ANNX more profitable?

Do analysts rate SRZN or ANNX?

Do institutionals and insiders believe in SRZN or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools